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Abstract
Background: Medulloblastoma is the most common malignant brain tumor of childhood. Improvements in
clinical outcome require a better understanding of the genetic alterations to identify clinically significant biological
factors and to stratify patients accordingly. In the present study, we applied cytogenetic characterization to guide
the identification of biologically significant genes from gene expression microarray profiles of medulloblastoma.
Methods: We analyzed 71 primary medulloblastomas for chromosomal copy number aberrations (CNAs) using
comparative genomic hybridization (CGH). Among 64 tumors that we previously analyzed by gene expression
microarrays, 27 were included in our CGH series. We analyzed clinical outcome with respect to CNAs and
microarray results. We filtered microarray data using specific CNAs to detect differentially expressed candidate
genes associated with survival.
Results: The most frequent lesions detected in our series involved chromosome 17; loss of 16q, 10q, or 8p; and
gain of 7q or 2p. Recurrent amplifications at 2p23-p24, 2q14, 7q34, and 12p13 were also observed. Gain of 8q is
associated with worse overall survival (p = 0.0141), which is not entirely attributable to MYC amplification or
overexpression. By applying CGH results to gene expression analysis of medulloblastoma, we identified three 8qmapped genes that are associated with overall survival in the larger group of 64 patients (p < 0.05): eukaryotic
translation elongation factor 1D (EEF1D), ribosomal protein L30 (RPL30), and ribosomal protein S20 (RPS20).
Conclusion: The complementary use of CGH and expression profiles can facilitate the identification of clinically
significant candidate genes involved in medulloblastoma growth. We demonstrate that gain of 8q and expression
levels of three 8q-mapped candidate genes (EEF1D, RPL30, RPS20) are associated with adverse outcome in
medulloblastoma.
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Background

Methods

Medulloblastoma is the most common malignant brain
tumor of childhood. Treatment with surgery, radiation,
and chemotherapy successfully cures many patients, but
survivors can suffer significant long-term toxicities affecting their neurocognitive and growth potential. Despite
clinical advances, up to 30% of children with medulloblastoma experience tumor progression or recurrence, for
which no curative therapy exists [1]. The lack of more
effective, less toxic therapies and the inability to stratify
patients biologically result from imperfect understanding
of the molecular processes that underlie medulloblastoma growth [1-3].

Patient samples
Seventy-one medulloblastoma samples were obtained following informed consents via Institutional Review Board
(IRB)-approved protocols from patients (aged 7 months –
38 years) diagnosed between 1991 and 2004 at Children's
Hospital (Boston, MA) and Texas Children's Hospital
(Houston, TX). Of these, 27 tumors were also previously
analyzed by expression profiling using oligonucleotide
microarrays [6] [Figure 1]. All specimens were obtained at
the time of diagnosis prior to radiation or chemotherapy
and subjected to histopathologic review according to
WHO criteria [3]. Tumor samples were snap-frozen and
stored in liquid nitrogen.

The advent of genomic technologies has permitted a more
global approach to tumor classification, diagnosis, and
prognostication [4-6]. Several medulloblastoma series
have been analyzed for copy number aberrations (CNAs)
with comparative genomic hybridization (CGH), widely
considered a standard method for genome-wide screening
[7-12]. Using CGH, we have determined that gain of the
long arm of chromosome 8 is associated with overall and
progression-free survival of medulloblastoma patients.
Despite its limited resolution, chromosomal CGH can
guide gene expression analysis, suggesting potential oncogenes or tumor suppressor genes involved in tumor
growth. Our identification of 8q gain as clinically significant prompted the search for candidate genes mapped to
that chromosomal region. Previous reports have identified MYC amplification and overexpression as clinically
significant. However, we did not note such associations in
our series. We investigated the possibility of other 8qmapped candidate genes by exploiting the microarray
analysis of an overlapping set of medulloblastoma specimens to complement the scale of our CGH dataset.
Of the 71 tumors we analyzed by CGH, a subset of 27
were among 64 medulloblastomas previously analyzed
using gene expression microarrays, which permitted integrated analysis of both sets of data [6]. We identified three
8q-mapped genes overexpressed in tumors with 8q gain
and whose expression levels were significantly associated
with overall survival in all 64 patients: eukaryotic translation elongation factor 1D (EEF1D), ribosomal protein
L30 (RPL30), and ribosomal protein S20 (RPS20). We
corroborated the expression of each candidate gene in
microarray analysis by quantitative real time-RTPCR
(qRT-RTPCR). By analyzing expression microarray data
and cytogenetic profiles, we have identified a group of
clinically significant genes involved in translational regulation that display relatively small expression changes and
previously eluded implication by single platform
approaches.

All patients were initially treated with maximally feasible
surgical resection. Subtotal or partial resection was
achieved in eleven patients. Chemotherapy for most
patients (n = 50) consisted of repeated cycles of cisplatin
and vincristine, with combinations of carboplatin, etoposide, cyclophosphamide and/or lomustine [13-16]. The
other twenty-one patients received intensified chemotherapy cycles (vincristine, cisplatin, cyclophosphamide, and
etoposide) with autologous stem cell support [17].
Patients greater than 36 months old received craniospinal
irradiation 2,400 ± 360 centiGray (cGy) with a tumor
dose of 5,300 ± 720 cGy. For the entire group, median follow up was 36 months (mean 39 months, range 4 – 109).
All studies were performed with the approval of the Committee for Clinical Investigation and the IRB of Boston

Figure 1
Experimental
design
Experimental design. Genomic characterization of 71
medulloblastomas was performed with CGH and the most
frequent CNAs were subjected to survival analysis. Twentyseven tumors also had gene expression profile data, and
were used to identify differentially expressed genes based on
tumor chromosomal profiles. For survival analysis, the 64
medulloblastoma patients were stratified according to the
expression values for each candidate gene.
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Children's Hospital, Harvard Medical School, and the IRB
of Baylor College of Medicine for Texas Children's Hospital.
Comparative Genomic Hybridization (CGH) and survival
analysis
Tumor DNA was extracted using the DNeasy Tissue Protocol (Qiagen, Valencia, CA). In cases of limited tissue, DNA
was extracted using TRIZOL according to the manufacturer's instructions (Invitrogen, Carlsbad, CA), or from
paraffin-embedded tissues using standard methods with
proteinase K digestion, phenol: chloroform extraction,
and ethanol precipitation [18]. Total cellular RNA from a
matching portion of frozen tissue was extracted using TRIZOL or RNeasy (Qiagen). The established medulloblastoma cell line Daoy (American Type Culture Collection,
Manassas, VA) was maintained to provide control RNA, as
previously described [19].

Normal metaphase spreads and chromosomal CGH were
performed on 71 tumor specimens as previously
described [20]. Briefly, DNA from normal female human
placental controls and medulloblastoma samples were
labeled by nick-translation with Texas red-5-dUTP and
fluorescein (FITC)-12-dUTP, respectively (Dupont NEN,
Boston, MA), and co-hybridized onto normal metaphase
chromosomes. Images from at least ten to fifteen separate
metaphases were captured by CCD camera (SenSys Photometrics, Tucson, AZ) mounted on a Nikon Eclipse 800
microscope. The fluorescence signal ratio (FITC:Texas red)
along each chromosome was calculated with Quantitative
Image Processing System (Applied Imaging, Santa Clara,
CA). The average of fluorescence ratios and their 99% confidence intervals were determined for each tumor specimen. Threshold ratio values greater than 1.2 and lower
than 0.8 defined tumor gains and losses, respectively.
High-level amplification was defined as fluorescence
ratios in excess of 2.0 at the chromosomal site.
For survival analysis of each CNA, patients were stratified
into two groups based on the presence or absence of the
specific cytogenetic lesion. Only those lesions detected in
a minimum of five patients (7%) were analyzed. Clinical
outcome measures, including overall and progression-free
survival, were determined from the date of diagnosis
using the method of Kaplan and Meier (SPSS v.11; SPSS,
Inc, Chicago, IL). The significance of survival differences
between patient groups was calculated by log-rank test. To
test if 8q gain was an independent prognostic factor, we
also performed multivariate analysis using Cox proportional hazard model for 8q gain with respect to three
other clinical prognostic factors: extent of resection, age
relative to 3 years and metastatic stage at diagnosis.

http://www.biomedcentral.com/1471-2407/6/223

Gene expression microarray analysis and candidate gene
identification
Twenty-seven of the 71 tumors characterized by CGH
were previously analyzed for their gene expression profiles on Affymetrix HuGeneFL microarrays and were
among the series of 64 reported by Pomeroy et al. [6]. We
normalized the CEL files of 64 tumors and four normal
cerebellar controls. The probe set intensities used for comparisons were calculated by model-based expression
index
using
dCHIP
software
(v1.3,
http://
www.dCHIP.org) [21]. Among the 44 tumors that were
collected subsequently and not included in the previous
report, seven were analyzed on the Affymetrix U133 Plus
2.0 microarrays and their resulting datasets were processed similarly for direct comparison with parallel qRTRTPCR results.

Differentially expressed candidate genes mapped to 8q
were subsequently analyzed for overall and progressionfree survival in the larger group of 64 profiled tumors
based on their expression levels (Kaplan-Meier test, SPSS).
Patients were stratified into two groups based on their
tumor expression level relative to that mean value. Candidate genes achieving p values less than 0.05 (log-rank test,
SPSS) were validated using qRT-RTPCR. Fisher's exact test
was used to calculate the significance of the association
between gene expression levels with tumor and clinical
variables.
Quantitative Real Time-RTPCR (qRT-RTPCR)
Tumor RNA was analyzed by qRT-RTPCR performed in a
Bio-Rad iQ4 Multicolor Real Time iCycler (Bio-Rad Laboratories, Hercules, CA). Total cellular RNA was reverse
transcribed with M-MLV Reverse Transcriptase enzyme
(Invitrogen) and oligo-(dT)12, according to the manufacturer's recommendations. PCR reactions containing
cDNA, iQ Syber Green Supermix (Bio-Rad), and primers
for EEF1D, RPL30, RPS20, MYC, or MYCN were performed in triplicate for 40 cycles (95°C 15 sec, 60°C 1
min). Amplification products were verified by melting
curves, agarose gel electrophoresis, and sequencing. Copy
numbers were internally normalized to GAPDH expression, quantitated relative to the Daoy cell line as a calibrator tissue control, and accounting for differences in primer
efficiencies [22]. Results from at least three separate experiments were analyzed. Fisher's exact test was used to calculate the significance of the association between gene
expression levels with tumor and clinical variables. We
determined correlation coefficients (R2) between expression levels detected by microarray and by qRT-RTPCR
using the Pearson method (relative to the Daoy cell line as
a tissue control). Primer sequences are: EEF1D, sense 5'CCCGCGTCCGCCGATTCCTC-3' and antisense 5'-CGCTGGCGCCGTTCTCCTG-3'; RPL30 sense, 5'-TGGTGGCTGCAAAGAAGAC-3'
and
antisense
5'-
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GCAGTTGTTAGCGAGAATGAC-3'; RPS20 sense, 5'CACGCTCCTGCTCCTGACTC-3' and antisense 5'-GCGGCTTGTTAGGCTGATTCG-3'; MYC sense, 5'-TCTGGATCACCTTCTGCTGG-3'
and
antisense
5'TGTTGCTGATCTGTCTCAGG-3'; MYCN sense, 5'-AGAGGACACCCTGAGCGATT-3' and antisense 5'-TCTTGGGACGCACAGTGATG-3';GAPDH
sense,
5'AAGGTGAAGGTCGGAGTCAA-3' and antisense, 5'-AATGAAGGGGTCATTGATGG-3'.

Results
Patient analysis and clinical data
We analyzed overall and progression-free survival for
patient groups stratified by clinical variables such as age,
sex, metastatic (Chang) stage, histologic subtype, and
treatment regimens. Not surprisingly, metastatic disease
at diagnosis displayed a trend toward worse survival
[Table 1]. For other reported risk factors, only age less
than three years was weakly associated with adverse clinical outcome, which could be attributed to the lack of
craniospinal radiation therapy in these patients. Neither
sex nor tumor histology correlated with outcome. Furthermore, different treatment centers and regimens (standard
dose chemotherapy plus radiation vs. intensified chemotherapy with autologous stem cell support) were not associated with differences in survival.
Overview of CNAs in medulloblastoma
The 71 medulloblastomas analyzed by chromosomal
CGH displayed a variety of CNAs [Figure 2; Table 2]. The
most frequently observed CNAs involved chromosome 17
(i.e. loss of the short arm, 17q gain). The loss of 17p
accompanied by concurrent gain of 17q, consistent with
isochromosome 17q (i17q), was detected in 32% of
tumors. Losses were more frequently observed than gains
and predominated on chromosomes 16, 10, 8, and 11.

We also detected gain of 2p in 22% of tumors, including
5.6% with amplification at 2p23-p24, which was the most
common amplification detected in our series (n = 4).
Other recurrent amplifications were detected at 2q14,
7q34, and 12p13 in two specimens each and at 8q23-q24
in one tumor. Given the resolution of chromosomal CGH
(approximately 10–20 Mb), the 2p23-p24 amplifications
and the 8q23-q24 amplification probably include the
MYCN (2p24.1) and MYC (8q24.12-q24.13) loci, respectively. Amplifications and low copy number gains at
2p23-p24 or 8q23-q24 were not associated with large cell
or anaplastic histology.
CNA-based survival analysis reveals association with gain
of 8q
To evaluate the clinical significance of common CNAs, we
stratified 71 medulloblastoma patients according to the
presence or absence of specific cytogenetic lesions in their
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tumors. Specific CNAs involving 58 chromosomal regions
were observed in a minimum of 7% tumors and used to
stratify patients for Kaplan-Meier survival analysis [Table
2]. The most common lesions, including loss of 17p and/
or gain of 17q, were not significantly associated with outcome.
Another common CNA, gain of 2p (minimal region 2p23p24) detected in 22.5% of tumors (n = 16) displayed a
trend towards worse overall survival (p = 0.0848) [Table 3,
Figure 3]. Amplification at 2p23-p24 seen in 5.6% of
tumors (n = 4) was also associated with worse overall survival (p = 0.0152). However, gain of 2p without 2p23-p24
amplification in 17% of tumors (n = 12) was not associated with outcome.
Gain of 8q (minimal region 8q23-q24, in 10% of tumors)
displayed the strongest association with significantly
worse overall and progression-free survival (p = 0.0141
and 0.0004, respectively) [Table 3, Figure 4]. The gain of
8q was also associated with adverse outcome in the well
described high-risk group of patients were younger than
three years of age at diagnosis (n = 14) (p = 0.0023). One
of seven tumors with 8q gain also displayed large cell/anaplastic histology with partial loss of 8p23-q22 and amplification at 8q23-q24, which includes the MYC locus
(8q24.12-q24.13). When the single case of 8q amplification is excluded from the analysis, the other six patients
with gain of 8q22-q24 displayed an even stronger association with overall survival (p = 0.0005).
We performed multivariate analysis to test the significance
of 8q gain with regard to outcome. When controlled for
widely accepted prognostic factors (i.e. extent of resection,
age relative to 3 years and metastatic stage at diagnosis),
8q gain is still significantly associated with both PFS and
OS (p = 0.003 and 0.013, respectively) [see Additional file
1].
Adverse outcome is not associated with MYC or MYCN
expression
To address the potential contribution of MYC or MYCN,
we screened gene expression microarray data of 27 medulloblastoma specimens that were among 64 previously
reported tumors [6]. We did not discern significant upregulation of MYCN or other 2p-mapped gene expression in
the seven tumors with 2p gain or amplification relative to
the twenty tumors without 2p gain [Table 4]. Nor did we
detect an association between MYCN expression and overall survival in the larger group of 64 medulloblastomas.
We corroborated the microarray data with qRT-RTPCR in
12 primary medulloblastomas and determined that
MYCN was not significantly overexpressed in tumors with
gain or amplifications of 2p, compared to others (p =
0.31) [Table 4].
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71 tumors analyzed by CGH

27 tumors analyzed by both CGH and microarray

64 tumors analyzed by microarray

80 (89.4; 7–458)

73 (93.6; 7–458)

74 (99.9; 7–458)

36 (39; 4–109)

39 (40.2; 7–80)

39 (46; 5–130)

14 [0.139:0.187]

7 [0.542:0.421]

11 [0.406:0.0005]*

54 : 17 [0.027*:0.111]

20 : 7 [0.058:0.222]

43 : 21 [0.047*:0.012*]

SEX- male: female [p value- OS:PFS]

51 : 20 [0.875:0.532]

18 : 9 [0.729:0.839]

42 : 22 [0.827:0.957]

SURGERY- Gross Total Resection: Subtotal Resection [p value- OS:PFS]

60 : 11 [0.0701:0.386]

18 : 9 [0.028*:0.427]

40 : 24 [0.0502:0.926]

50:21 [0.825:0.972]

27:0 [NA]

64:0 [NA]

Classic [p value- OS:PFS]

30 [0.714:0.619]

16 [0.461:0.996]

44 [0.384:0.377]

Nodular or Desmoplastic [p value- OS:PFS]

21 [0.558:0.731]

8 [0.327:0.987]

15 [0.46:0.564]

Large cell or Anaplastic [p value- OS:PFS]

17 [0.844:0.830]

NA

NA

Intermediate or Other [p value- OS:PFS]

3 [0.935:0.995]

3 [0.769:0.985]

5 [0.736:0.532]

Median Age in months (mean; range)

Median Follow-up in months (mean; range)

Number of patients < 3 yr old [p value- OS:PFS]

STAGE (Chang) – M0: M+ [p value- OS:PFS]

CHEMOTHERAPY- Standard : PBSCT [p value- OS:PFS]

BMC Cancer 2006, 6:223

HISTOLOGY

Abbreviations: CGH, comparative genomic hybridization; OS, overall survival; PFS, progression-free survival; PBSCT, peripheral blood stem cell transplant; NA, not applicable.
Log-rank p values were calculated for OS and PFS.
*Statistically significant p values.
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Table 1: Patient summary
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Figure 2 of Comparative Genomic Hybridization
Summary
Summary of Comparative Genomic Hybridization. Ideogram showing genetic imbalances detected in 71 medulloblastoma by comparative genomic hybridization (CGH). Red bars on the left of the chromosomes represent losses and green bars
on the right correspond to gains of chromosomal regions in tumors; amplifications are depicted as bold green bars. Multiple
cases with the same CNA are grouped as thick bars, with total number of cases displayed at the top.
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Table 2: Most Common Chromosomal Copy Number Aberration Among 71 Medulloblastomas.

Chromosome Loss
17p loss
17p loss and 17q gain (consistent with isochromosome 17q)
16q loss
10q loss
8p loss
16p loss
6q loss
10p loss
9q loss
11p loss
19p loss
3q loss
6p loss
11q loss
13q loss
17q loss
15q loss
1p loss
20q loss
X loss
3p loss
21q loss
Chromosome Gain
17q gain
17q gain and 17p loss (consistent with isochromosome 17q)
7q gain
2p gain
7p gain
18q gain
X gain
2q gain
17p gain
5p gain
18p gain
1q gain
9p gain
19 gain
8q gain
3q gain
5q gain
6q gain

Number (%)

p value, log-rank [OS: PFS]

36 (50%)*
23 (32%)*
29 (40%)
25 (35%)
24 (34%)
22 (31%)
16 (22%)
16 (22%)
16 (22%)
15 (21%)
13 (18%)
13 (18%)
13 (18%)
13 (18%)
10 (14%)
10 (14%)
8 (11%)
8 (11%)
8 (11%)
8 (11%)
7 (10%)
7 (10%)

0.544: 0.816
0.704: 0.874
0.707: 0.889
0.356: 0.252
0.581: 0.423
0.744: 0.736
0.741: 0.345
0.325: 0.386
0.999: 0.703
0.201: 0.212
0.332: 0.282
0.899: 0.439
0.506: 0.095
0.330: 0.375
0.966: 0.611
0.918: 0.889
0.064: 0.596
0.061: 0.167
0.992: 0.780
0.958: 0.613
0.476: 0.343
0.397: 0.573

Number (%)

p value, log-rank [OS: PFS]

34 (48%)*
23 (32%)*
21 (30%)
16 (22%)
16 (22%)
11 (15%)
10 (14%)
10 (14%)
9 (13%)
9 (13%)
9 (13%)
8 (11%)
8 (11%)
8 (11%)
7 (10%)
7 (10%)
7 (10%)
7 (10%)

0.794: 0.340
0.704: 0.874
0.927: 0.366
0.394: 0.526
0.394: 0.195
0.896: 0.842
0.786: 0.868
0.166: 0.356
0.545: 0.885
0.863: 0.688
0.963: 0.652
0.242: 0.088
0.913: 0.893
0.480: 0.403
0.0141**: 0.0004**
0.212: 0.464
0.657: 0.790
0.551: 0.990

* In 23 cases, 17q gain was detected with concurrent 17p loss, and was consistent with i17q.
** Statistically significant differences by log-rank testing.

We also examined the possible contribution of MYC
expression to the clinical significance of 8q gain. Higher
levels of MYC expression correlated with slightly worse
outcome among the larger group of 64 medulloblastomas, although failed to achieve statistical significance (in
agreement with previous results) [6]. In addition, MYC
was not consistently overexpressed in microarray-analyzed tumors with 8q gain (n = 3) [Table 4]. We quantitated MYC in twelve available tumor specimens with qRT-

RTPCR and found that MYC was not significantly upregulated in the two tumors with 8q gain (t = 0.49). Not surprisingly, the one tumor with 8q23-q24 amplification
displayed the highest MYC level, while low copy number
gains of 8q did not correlate with higher MYC levels in
either microarray- or qRT-RTPCR-tested specimens. As
tested by qRT-RTPCR, relative MYC expression correlated
highly with microarray results (R2 = 0.99). Overall, these
data suggest that MYC expression, like 8q amplification, is
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those candidate genes significantly associated with clinical outcome.
In the larger group of 64 microarray-profiled tumors, the
expression levels of three of five 8q-mapped genes were
adversely associated with overall and progression-free survival: eukaryotic translation elongation factor 1D
(EEF1D;p values, 0.014 (OS) and 0.0085 (PFS), log-rank),
ribosomal protein L30 (RPL30;p values, 0.014 (OS) and
0.0018 (PFS)), and ribosomal protein S20 (RPS20;p values, 0.0005 (OS) and 0.0213 (PFS)) [Table 4; Figures 5, 6,
7]. In fact, we detected elevated levels of these genes in
many tumors without 8q gain. This suggests that not only
do these candidate genes contribute to outcome in
patients with 8q gain tumors, but also in those regardless
of their cytogenetic profiles. The expression levels of
EEF1D, RPL30, and RPS20 did not correlate with MYC
expression in the 64 microarray-profiled tumors.

Figure
Survival
of
chromosome
3analysis of
2 patients stratified by gain of the long arm
Survival analysis of patients stratified by gain of the
long arm of chromosome 2. Kaplan-Meier analysis of
overall survival (OS) in 71 patients with medulloblastoma
stratified by gain of 2p: sixteen patients with 2p gain compared to 55 others without 2p gain. Follow-up is expressed
as time from diagnosis in months.

not entirely responsible for the association of 8q gain with
survival.
Independent of 8q status, adverse outcome is associated
with expression of 8q-mapped genes: EEF1D, RPL30, and
RPS20
Since MYC amplification and expression were not associated with overall survival in our series, we analyzed gene
expression data to identify other candidate genes affected
by this specific CNA. Of the 27 medulloblastomas with
both CGH and microarray data, 11% displayed 8q gain,
whose expression profiles were compared to the other
89% of tumors. Of the 149 genes with at least 1.5-fold differential expression levels, 27 genes were upregulated in
8q gain tumors and five genes mapped to 8q. Since gene
dosage effects related to chromosomal gains may contribute to higher relative gene expression, we sought to define

Because the 64 tumor specimens profiled on Affymetrix
HuGeneFL, were unavailable for further analysis by qRTRTPCR, we could not validate candidate gene expression
directly. Alternatively, we assayed the expression of
EEF1D, RPL30, and RPS20 with qRT-RTPCR in twelve
available medulloblastoma specimens, including those
analyzed by Affymetrix U133 Plus 2.0 microarrays [Table
4]. To corroborate the tumor profiles, we compared the
expression of each candidate gene by qRT-RTPCR with the
new set of microarray-generated data on Affymetrix U133
Plus 2.0. As expected, each candidate gene demonstrated
a broader range of differential expression by qRT-RTPCR
than by microarray, consistent with signal compression
[23]. Our qRT-RTPCR results correlated well with the
expression patterns noted in microarray data (R2, 0.53–
0.90) [Table 4], indicating that observed expression levels
detected by microarray analysis likely reflect tumor differences.

Discussion
We report the results of our CGH analysis of a large series
of medulloblastoma and the application of CNA-based
outcome analysis of expression datasets to identify candidate genes. The relative frequencies of various CNAs are
consistent with previous CGH reports [7,9-12]. The most
common aberrations involved chromosome 17, including loss of 17p and gain of 17q, which were not signifi-

Table 3: Copy Number Aberrations associated with overall and progression-free survival.

Copy Number Aberration
2p gain (including amplifications)
8q gain (including amplifications*)

n

Overall Survival p value (log-rank)

Progression-Free Survival p value (log-rank)

12 (16)
6 (7)

0.5257 (0.0848)
0.0005** (0.0141**)

0.3938 (0.0701)
< 0.0001** (0.0004**)

* Multivariate analysis controlling for clinical variables (i.e. metastatic stage, degree of resection, and age relative to 3 years) revealed statistically
significant differences in OS (p value, 0.013) and PFS (p value, 0.003).
** Statistically significant differences by log-rank testing.
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with overall survival. Although only a minority of specimens was available for confirmatory qRT-RTPCR quantitation, in those tumors tested, MYC levels correlated well
with microarray results. MYC expression levels, however,
were not associated with survival in our series, in contrast
with previous reports [33]. Overall, our results indicate
that biological factors associated with 8q gain other than
MYC achieve clinical significance in our series of medulloblastoma patients. Due to the relatively low frequency
of 8q gain, however, its prognostic significance requires
confirmation in studies with larger sample size.

Figure
Survival
of
chromosome
4analysis of
8 patients stratified by gain of the long arm
Survival analysis of patients stratified by gain of the
long arm of chromosome 8. Kaplan-Meier analysis of
overall survival (OS) in 71 patients with medulloblastoma
stratified by gain of 8q: seven patients with 8q gain and 64
others without 8q gain. Follow-up is expressed as time from
diagnosis in months.

cantly associated with outcome in our series. Several
reports have studied the clinical significance of CNAs, in
particular involving chromosome 17, but with discordant
results. Loss of 17p correlated with survival in several
series [24-27]. Mendrzyk et al [28] and Pan et al [10] have
described adverse outcomes associated with combined
17p loss and 17q gain, as in iso17q, respectively. Negative
studies include those of Biegel et al [29], Emadian et al
[30], Jung et al [31], and Nicholson et al [32]. In general,
these studies evaluated fewer samples or follow-up was
limited. In addition, multiple clinical factors probably
contribute to discrepancies among different series.
Our CGH-based outcome analysis reveals a significant
association between 8q gain (minimal common region
8q23-q24) and worse overall survival, confirmed by multivariate analysis by controlling for three known prognostic factors. We detected 8q gain in only seven cases of the
71 tumor specimens analyzed. The relatively low frequency of 8q gain probably prevented detection of its clinical significance in other series. MYC amplification has
been identified as a marker of poor prognosis, but previous studies did not further characterize cytogenetic
changes involving 8q. In fact, excluding the only patient
with tumor amplification at 8q23-q24 from the outcome
analysis actually strengthens the association of 8q gain

Our CGH and gene expression analysis indicate that other
genes mapped to 8q may contribute to clinical outcome.
We screened microarray profiles in an overlapping subset
of tumors to identify differentially expressed candidate
genes overexpressed in specimens with 8q gain. The
expression of three candidate genes were associated with
overall and progression-free survival: EEF1D, RPL30, and
RPS20. By analyzing the larger group of 64 patients, we
confirmed the association of these candidate genes with
outcome. In fact, among the 64 patients, higher expression of EEF1D, RPL30, and RPS20 correlated with worse
overall and progression-free survival regardless of cytogenetic profile. Since we also detected overexpression of
these candidate genes in tumor samples without 8q gain,
alternate mechanisms of induction may otherwise contribute to tumor phenotype and clinical outcome.
These candidate genes represent a novel group involved in
translational regulation and have not been previously
associated with outcome in medulloblastoma. Although
we previously reported that RPL30 expression was associated with classic histology, the smaller expression differences precluded prior detection and association with
survival [6]. In that study, we employed a two-class comparison of array profiles based on an unsupervised clustering algorithm (self-organizing map) to define a multigene predictor of adverse outcome. The multi-gene predictor included several other ribosomal genes, but did not
include EEF1D, RPL30, or RPS20. All three candidate
genes are involved in ribosomal functions: RPS20 encodes
a component of the 60S ribosomal subunit, and RPL30
part of the 40S subunit. The EEF1D protein contributes to
delivery of t-RNA to ribosomes. The overexpression of
EEF1D has been associated with advanced tumor stage in
gastrointestinal carcinomas and EEF1D reportedly displays oncogenic properties in vitro [34-36]. This supports
the hypothesis that increased expression of ribosomal
genes confers a growth advantage [37].
Indeed, accumulating evidence indicates that aberrant
regulation of ribosomes, their components, and their
functions can be linked to cellular transformation. Several
oncogenes and tumor suppressor genes, including MYC
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Cytoband

Affymetrix probe set

Overall Survival
(p value1)

Progression- Free
Survival (p value1)

Mean Fold Change by
Microarray (ratio of tumors
with CNA: tumors without
CNA)2 (p value)

Ribosomal protein S20 (RPS20)

8q12

HG1800-HT1823_at

0.0005*

0.0213*

1.58 (0.025)**

Ribosomal protein L30 (RPL30)

8q22

HG2873-HT3017_at

0.014*

0.0018*

1.78 (0.0162)**

Euskaryotic translation elongation factor 1 delta (EEF1D)

8q24.3

Z21507_at

0.014*

0.0085*

1.71 (0.0089)**

MYC

8q24.12-q24.13

L00058_at and HG3523-HT4899_s_at

0.218–0.378

0.223–0.506

1.35 and 2.99 (0.38 and 0.26)

MYCN

2p24.1

M13241_at

0.403

0.661

1.56 (0.31)

1 Kaplan-Meier

analysis of 64 patients stratified by microarray-based gene expression levels using Affymetrix HuGeneFL microarrays. Significance determined by log-rank test.
calculated from expression levels in 27 patient samples with and without the specific CNA (8q or 2p gain), using HuGeneFL microarrays. Significance determined by log-rank test.
* Statistically significant differences in overall survival based on microarray expression levels.
** Statistically significant differences in microarray expression levels among tumors analyzed by both CGH and microarray.

2 Ratio
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eukaryotic
Survival
Figure 5analysis
translation
of patients
elongation
stratified
factor
by expression
1 delta (EEF1D)
of
Survival analysis of patients stratified by expression
of eukaryotic translation elongation factor 1 delta
(EEF1D). Kaplan-Meier analysis of overall survival in 64
patients with medulloblastoma based on Hu6800FL array
data for the 8q-mapped candidate gene, eukaryotic translation elongation factor 1 delta (EEF1D). We calculated the
mean between the median expression level of tumors with
8q gain and the median level of those without it. Patients
were stratified into two groups based on their tumor expression level relative to that mean. Follow-up is expressed as
time from diagnosis in months.

and MYCN, regulate the expression of rRNA and ribosomal proteins [37]. Not surprisingly, cancer cells display
increased metabolism and protein synthesis, which
requires upregulated ribosomal proteins and rRNA [37].
Since ribosomal proteins and translation factors directly
regulate protein synthesis, influencing ribosomal biogenesis is one of the possible mechanisms by which cellular
growth controls can be disrupted, resulting in increased
proliferation. It remains unclear precisely how deregulation of rRNA and ribosomal functions are involved in
tumor formation or progression. Nonetheless, our results
suggest that better appreciation of the relative contributions of EEF1D, RPL30, RPS20, and their associated regulatory mechanisms will impact our understanding of
medulloblastoma biology. The identification of these
three candidate genes indicates that specific mechanisms
of ribosomal biosynthesis and translational regulation are
certainly worthy of future study in medulloblastoma.

Conclusion
In summary, our CGH survey of 71 medulloblastomas
indicates that the gain of 8q is adversely associated with

http://www.biomedcentral.com/1471-2407/6/223

Figure
Survival
omal
protein
6analysis
L30of(RPL30)
patients stratified by expression of ribosSurvival analysis of patients stratified by expression
of ribosomal protein L30 (RPL30). Kaplan-Meier analysis
of overall survival in 64 patients with medulloblastoma based
on Hu6800FL array data for the 8q-mapped candidate gene,
ribosomal protein L30 (RPL30). We calculated the mean
between the median expression level of tumors with 8q gain
and the median level of those without it. Patients were stratified into two groups based on their tumor expression level
relative to that mean. Follow-up is expressed as time from
diagnosis in months.

overall and progression-free survival in patients with
medulloblastoma. We applied our cytogenetic results to
guide the expression analysis of a subset of twenty-seven
tumors and subsequent outcome analysis in the larger
group of 64 tumors. By exploiting these complementary
genomic datasets, we have implicated the expression of
three 8q-mapped candidate genes (EEF1D, RPL30, and
RPS20) as adversely associated with overall and progression-free survival, independent of cytogenetic profile. Our
results indicate the potential for hypothesis-generation by
integrating these global approaches, so that more selective
methods may now be applied in future studies of their
contributions to tumor biology and clinical outcome.

Abbreviations
CGH, comparative genomic hybridization; CNA, copy
number aberration; EEF1D, eukaryotic translation elongation factor 1D; qRT-RTPCR, quantitative real-time reverse
transcription polymerase chain reaction; RPL30, ribosomal protein L30; RPS20, ribosomal protein S20.
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Additional material
Additional File 1
Multivariate Analysis of 8q Gain for Overall and Progression-Free
Survival Controlled for Other Prognostic Variables. Multivariate analysis of significance was performed for 8q gain with respect to clinical variables that are widely accepted as prognostically significant: age relative to
3 years old and metastatic stage at diagnosis, and the degree of primary
resection. These results confirm the prognostic significance of 8q gain for
Overall and Progression-Free Survival (p = 0.013 and p = 0.003. respectively). Abbreviations: CGH8q, 8q gain; age_3, age relative to 3 years;
resection, degree of resection; M_status, metastatic (Chang) stage; B,
regression coefficient of the model; SE, standard error; df, degrees of freedom; Sig, significance (p value based on Wald statistics); Exp(B), exponential function of B.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712407-6-223-S1.pdf]

Figure
Survival
omal
protein
7analysis
S20of(RPS20)
patientsexpression
stratified by expression of ribosSurvival analysis of patients stratified by expression
of ribosomal protein S20 (RPS20) expression. KaplanMeier analysis of overall survival in 64 patients with medulloblastoma based on Hu6800FL array data for the 8q-mapped
candidate gene, ribosomal protein S20 (RPS20). We calculated the mean between the median expression level of
tumors with 8q gain and the median level of those without it.
Patients were stratified into two groups based on their
tumor expression level relative to that mean. Follow-up is
expressed as time from diagnosis in months.
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